Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MASP2 | O00187 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | FURIN | P09958 | 1/20 | 0.38 |
| ▸ | PPIB | P23284 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | KIT | P10721 | 2/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.36 |
| ▸ | CPB2 | Q96IY4 | 5/20 | 0.36 |
| ▸ | CPB1 | P15086 | 1/20 | 0.36 |
| ▸ | LCK | P06239 | 1/20 | 0.35 |
| ▸ | SRC | P12931 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | METAP2 | P50579 | 1/20 | 0.35 |
| ▸ | METAP1 | P53582 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3157818 | 1.00 | MASP2 (0.43) | MASP2ALDH1A1LMNAFURINPPIB | |
| SCHEMBL6882736 | 0.87 | MASP2 (0.43) | MASP2ALDH1A1LMNAFURINPPIB | |
| SCHEMBL1432429 | 0.86 | CYP3A4 (0.42) | MASP2PPIBCYP3A4 | |
| SCHEMBL1431929 | 0.85 | MASP2 (0.46) | MASP2ALDH1A1LMNAPPIBCYP3A4 | |
| SCHEMBL3139463 | 0.85 | MASP2 (0.46) | MASP2ALDH1A1LMNAPPIBCYP3A4 | |
| SCHEMBL1432085 | 0.85 | MASP2 (0.44) | MASP2PPIBCYP3A4CPB2 | |
| SCHEMBL3148057 | 0.85 | MASP2 (0.43) | MASP2ALDH1A1LMNAPPIBCYP3A4 | |
| SCHEMBL3148062 | 0.85 | MASP2 (0.43) | MASP2ALDH1A1LMNAPPIBCYP3A4 | |
| SCHEMBL1432393 | 0.84 | MASP2 (0.43) | MASP2PPIBCPB2CPB1EPHX1 | |
| SCHEMBL1432406 | 0.84 | MASP2 (0.43) | MASP2PPIBCPB2CPB1EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2300428-A1 | AMINOPYRIDINE DERIVATIVES | Vantia Limited (GB) | 2011-03-30 | — | — | EP | disclosed |
| US-20100076015-A1 | Aminopyridine Derivatives | VANTIA LIMITED (GB) | 2010-03-25 | — | — | US | disclosed |
| WO-2009133348-A1 | AMINOPYRIDINE DERIVATIVES | VANTIA LIMITED (GB) | 2009-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100076015-A1 | Aminopyridine Derivatives | CHRM1, ARG1, ARG2 | MASP2 3039/4885ALDH1A1 147/4885LMNA 3185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.